Rucaparib FDA Approval: New PARP Inhibitor Options for BRCA-Mutated mCRPC
The FDA has granted full approval to rucaparib, an oral PARP inhibitor, for adults with BRCA1/2-mutated metastatic castration-resistant prostate cancer following progression on androgen receptor-directed...
